ArticleThe Journal of pathology2022
P2X4 purinergic receptors offer a therapeutic target for aggressive prostate cancer.
Article in The Journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 35 citations in OpenAlex.
- Subclonal Complete Loss of CDKN1B as a Common Genomic Alteration in Prostate Cancer: Associations With Race and Prostate Cancer Outcomes.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2026Article
- Aberrant alternative splicing of purinergic receptor P2RX4 prevents sensitivity towards combinatorial treatment in colorectal and pancreatic cancer.The Journal of pathology · 2026Article
- HLA Class I Expression Is Associated with Increased Immune Cell Density and PTEN Loss in Prostate Cancer.Molecular cancer research : MCR · 2026Article
- Ectonucleotidases CD39 and CD73 expression levels are independent and inverse predictors of survival in muscle-invasive bladder cancer.The journal of pathology. Clinical research · 2026Article
- The P2X4 purinergic receptor controls the autophagy-related release of small extracellular vesicles from mammary cancer cells under hypoxia.Cell communication and signaling : CCS · 2026Article
- Phenolic compounds and chemotherapeutic agents differentially regulate P2X receptor subtypes in malignant melanoma.Purinergic signalling · 2026Article
- High levels of P2RX5 expression predicts a poor prognosis and promotes tumor progression in endometrial cancer.International journal of clinical and experimental pathology · 2026Article
- Discovery of an allosteric binding site for anthraquinones at the human P2X4 receptor.Nature communications · 2025Article
- M1-like macrophages regulate T cell infiltration in colorectal cancer through P2X4 receptor.iScience · 2025Article
- Depletion of P2X4 receptor alleviates prostate cancer bone metastasis through reduced cancer cell invasiveness and enhanced cell adhesion activities.Purinergic signalling · 2025Article
- Possible Roles for Purinergic Receptor P2RX4 in Breast and Prostate Cancers.International journal of molecular sciences · 2025Review
- Ap4A in Cancer: A Multifaceted Regulator and Emerging Therapeutic Target.Molecules (Basel, Switzerland) · 2025Review
- P2 purinergic receptor expression and function in tumor-related immune cells.Purinergic signalling · 2025Review
- Towards P2X4 Positron Emission Tomography Tracing.Journal of medicinal chemistry · 2025Review
- The role and function validation of P2RX4 as a novel cancer biomarker in pan-cancer analysis.Scientific reports · 2025Article
- Article
- Piperazine-based P2X4 receptor antagonists.Archiv der Pharmazie · 2025Article
- Preparation and preliminary evaluation of a tritium-labeled allosteric P2X4 receptor antagonist.Purinergic signalling · 2024Article
- Whole-exome sequencing identifies cancer-associated variants of the endo-lysosomal ion transport channels in the Saudi population.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2024Article
- ATP released from dying cancer cells stimulates P2X4 receptors and mTOR in their neighbors.Purinergic signalling · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer (PCa) remains a leading cause of cancer-related deaths in American men and treatment options for metastatic PCa are limited. There is a critical need to identify new mechanisms that contribute to PCa progression, that distinguish benign from lethal disease, and that have potential for therapeutic targeting. P2X4 belongs to the P2 purinergic receptor family that is commonly upregulated in cancer and is associated with poorer outcomes. We observed P2X4 protein expression primarily in epithelial cells of the prostate, a subset of CD66
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.